Next Generation Antibody Therapeutics Market

SKU: DMBT1948 | Last Updated On: Nov 01 2022 | Available Formats

>Next Generation Antibody Therapeutics Market is Expected to reach a high CAGR of 13% by 2029|

Next-Generation Antibody Therapeutics Market is segmented By Technology (Antibody-Drug Conjugates, Bispecific Antibodies, Biosimilar Antibody Products, Fc-engineered Antibodies, Antibody Fragments, and Antibody-Like Proteins, Others), By Therapeutic Area (Autoimmune/Inflammatory Next-Generation Antibody Therapeutics, Oncology Next-Generation Antibody Therapeutics), By End-User (Hospitals, Clinics, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029.

 

Next Generation Antibody Therapeutics Market is expected to grow at a high CAGR of 13% during the forecasting period (2022-2029).

Next-Generation Antibody Therapeutics Market

Metrics

Details

Market CAGR

13%

Segments Covered

By Technology, By Therapeutic Area, By End-User, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To know more insights into the market, Get Our Sample Brochure  

Next-generation antibody therapeutics include using a new improvised therapeutic antibody to form innovative medicines for treating various diseases. Next-generation antibody therapeutics are developed clinically by pharmaceutical and biotechnology companies for several diseases.

Market Dynamics

The global next-generation antibody therapeutics market is growing due to several factors such as the rising incidence of chronic diseases, the increasing emergence of antibody technology, new drug discovery, a large number of government initiatives, and growing research and development activities for new therapies.

The rising prevalence of chronic diseases is expected to drive the market growth     

The rising prevalence of chronic diseases such as cancer, asthma, diabetes, and COPD boosts the growth of the next-generation antibody therapeutics market. As per CDC 2021 data, the risk of being diagnosed with cancer generally increases with age, and over this period the US population has grown, particularly in the older age groups. Thus, the increase in the number of incident cases and deaths reflects, to a large extent, the impact of a growing and aging population. Trends in cancer incidence rates (population risk) and projections of population growth and age structure have been used to predict cancer incidence including in the US (4), Canada (5), England (6), the Nordic countries (7), and for world regions broadly (8).

The development of next-generation monoclonal antibodies has expanded beyond oncology into all therapeutic areas. For instance, ADCs were initially focused primarily on cancer. Still, Genentech has applied to infectious diseases, leading to THIOMAB antibiotic conjugates (TACs) to treat methicillin-resistant Staphylococcus aureus (MRSA).

The technological advancements in antibody therapeutics have led to the development of more efficient antibody therapeutics, hence, driving the growth in the next-generation antibody therapeutics market. Advanced technology in antibody therapeutics, such as antibody-drug conjugate (ADC) technology, glycoengineered antibody technology, and bispecific antibodies (BsAbs) technology, has resulted in the development of antibody therapeutics with improved characteristics. Antibody therapeutics are entering the clinical study and being approved increasingly. The commercial pipeline is robust with over 570 antibody therapeutics at various clinical phases, including 62 in late-stage clinical studies. Phase 1 to approval success rates are favorable, ranging from 17–25%, depending on the therapeutic area (cancer vs. non-cancer).

The stringent government regulation will hamper the growth of the market  

However, stringent government regulation, high cost, and time required for research and development activities hinder the growth of the global next-generation antibody therapeutics market.

Segment Analysis

The antibody-drug conjugates (ADCs) segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)          

The advancement in ADC technology is one of the major trends in the next-generation antibody therapeutics market. The ADC technology combines the cytotoxic potential of chemotherapy and advantageous characteristics of antibodies, which leads to the high specificity and efficiency of ADCs.

The ADC technology is majorly used for the manufacturing of next-generation antibody therapeutics for treating cancer. The ADCs are manufactured by linking an anti-cancer drug or another therapeutic agent to an antibody or antibody fragment. Because of the high efficiency delivered by ADCs, various pharmaceutical companies, such as Seattle Genetics Inc., ImmunoGen Inc., F. Hoffmann-La Roche Ltd, and Bristol-Myers Squibb Company, are actively involved in the development of next-generation antibody therapeutics using ADC technology. Since automated dispensing cabinets are not located in the pharmacy, they are considered "decentralized" medication distribution systems. Instead, they can be found at the point of care in the resident care unit Thus, these factors are driving the growth of the market in the forecast period.

Geographical Analysis

North America region holds the largest market share of the global next-generation antibody therapeutics market

North America dominates the market for insulin pens and is expected to show a similar trend over the forecast period owing to the increasing research & development activities, technological advancement in antibody therapies, rising healthcare expenditure, and increasing government initiatives in this region. Besides, the rising incidence of chronic diseases and increasing approvals for new drugs also drive the market's growth. A total of 12 new antibodies were granted approvals in either the US or the EU during 2018. Perhaps reflecting the higher approval success rate for antibodies that are treatments for non-cancer indications, the majority (75%) of the products are for such diseases, including 3 for migraine prevention and 1 for human immunodeficiency virus (HIV) infection.

Cancer has a major impact on society in the United States and across the world. Cancer statistics describe what happens in large groups of people and provide a picture in time of the burden of cancer on society. Statistics tell us things such as how many people are diagnosed with and die from cancer each year, the number of people who are currently living after a cancer diagnosis, the average age at diagnosis, and the number of people who are still alive at a given time after diagnosis. Thus, these factors will drive the growth of the market in the forecast period.

Competitive Landscape

The next-generation antibody therapeutics market is a moderately competitive presence of local as well as global companies.  Some of the key players which are contributing to the growth of the market are Bayer AG, Amgen Inc., AstraZeneca PLC., Takeda Pharmaceuticals Company Limited, Pfizer Inc., Biogen, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, ImmunoGen Inc., Seattle Genetics Inc., among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the next-generation antibody therapeutics market globally.

Pfizer Inc.  

Overview:

Pfizer Inc (Pfizer) discovers, produces, manufactures and commercializes biopharmaceuticals. The company offers products for cardiovascular, metabolic and pain, cancer, inflammation, immune disorders, and rare diseases.     

Product Portfolio:

Antibody-Drug Conjugates: The Company manufactures ADC which are chemical linkers to connect cytotoxins with an antibody. The specificity of the antibody enables the ADC to target and bind to cell-surface proteins called antigens that can be found on cancer cells and release its cell-killing drugs only after it has been internalized by the cancer cell. As a result, ADCs have the potential to selectively kill cancer cells.

The global next-generation antibody therapeutics market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.  

Frequently Asked Questions

What is the Projected CAGR value of the Next-Generation Antibody Therapeutics Market?

Next-Generation Antibody Therapeutics Market is expected to grow at a CAGR of 13% during the forecasting period 2022-2029.

Which region controlled the global market during 2022-2029?

North America region Controls the Next-Generation Antibody Therapeutics Market during 2022-2029

Which is the fastest growing region in the Next-Generation Antibody Therapeutics Market?

Among all regions, Asia Pacific is the fastest growing market share during the forecast period 

Trending Topics

Monoclonal Antibody Therapeutics Market

Antibody Drug Conjugates

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest